JP2016529229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529229A5 JP2016529229A5 JP2016525822A JP2016525822A JP2016529229A5 JP 2016529229 A5 JP2016529229 A5 JP 2016529229A5 JP 2016525822 A JP2016525822 A JP 2016525822A JP 2016525822 A JP2016525822 A JP 2016525822A JP 2016529229 A5 JP2016529229 A5 JP 2016529229A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- immunoglobulin fusion
- region
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 23
- 108020001507 fusion proteins Proteins 0.000 claims 23
- 102000037865 fusion proteins Human genes 0.000 claims 23
- 102000018358 immunoglobulin Human genes 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 230000004927 fusion Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000006395 Globulins Human genes 0.000 claims 2
- 108010044091 Globulins Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019181052A JP6952221B2 (ja) | 2013-07-11 | 2019-09-30 | コイルドコイルの免疫グロブリン融合タンパク質およびその組成物 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845287P | 2013-07-11 | 2013-07-11 | |
| US201361845280P | 2013-07-11 | 2013-07-11 | |
| US61/845,287 | 2013-07-11 | ||
| US61/845,280 | 2013-07-11 | ||
| US201461925904P | 2014-01-10 | 2014-01-10 | |
| US61/925,904 | 2014-01-10 | ||
| US201462017713P | 2014-06-26 | 2014-06-26 | |
| US62/017,713 | 2014-06-26 | ||
| PCT/US2014/046419 WO2015006736A2 (en) | 2013-07-11 | 2014-07-11 | Coiled coil immunoglobulin fusion proteins and compositions thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019181052A Division JP6952221B2 (ja) | 2013-07-11 | 2019-09-30 | コイルドコイルの免疫グロブリン融合タンパク質およびその組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529229A JP2016529229A (ja) | 2016-09-23 |
| JP2016529229A5 true JP2016529229A5 (enExample) | 2017-08-10 |
| JP6704101B2 JP6704101B2 (ja) | 2020-06-03 |
Family
ID=52280653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525822A Active JP6704101B2 (ja) | 2013-07-11 | 2014-07-11 | コイルドコイルの免疫グロブリン融合タンパク質およびその組成物 |
| JP2019181052A Active JP6952221B2 (ja) | 2013-07-11 | 2019-09-30 | コイルドコイルの免疫グロブリン融合タンパク質およびその組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019181052A Active JP6952221B2 (ja) | 2013-07-11 | 2019-09-30 | コイルドコイルの免疫グロブリン融合タンパク質およびその組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20160237156A1 (enExample) |
| EP (3) | EP3019531A4 (enExample) |
| JP (2) | JP6704101B2 (enExample) |
| KR (1) | KR102361237B1 (enExample) |
| CN (2) | CN105593242B (enExample) |
| AU (1) | AU2014286998B2 (enExample) |
| CA (1) | CA2917814C (enExample) |
| DK (1) | DK3019533T3 (enExample) |
| ES (1) | ES2780948T3 (enExample) |
| PT (1) | PT3019533T (enExample) |
| WO (2) | WO2015006736A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL133974A0 (en) | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
| US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
| ATE526401T1 (de) | 1999-01-14 | 2011-10-15 | Bolder Biotechnology Inc | Verfahren zur herstellung von proteinen mit freien cysteinresten |
| US10774132B2 (en) | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
| WO2013106489A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
| US10259863B2 (en) * | 2013-01-11 | 2019-04-16 | The California Institute For Biomedical Research | Bovine fusion antibodies |
| EP3019531A4 (en) | 2013-07-11 | 2017-03-15 | The California Institute for Biomedical Research | Immunoglobulin fusion proteins and compositions thereof |
| JP6687520B2 (ja) | 2013-07-18 | 2020-04-22 | トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー | 極めて長い相補性決定領域を有するヒト化抗体 |
| WO2017037158A1 (en) | 2015-09-01 | 2017-03-09 | Oncoqr Ml Gmbh | Coiled-coil connector |
| EP3359191A4 (en) * | 2015-10-05 | 2019-05-29 | Merck Sharp & Dohme Corp. | ANTIBODY PEPTIDE CONJUGATES WITH AGONISTEACTIVITY ON GLUCAGON RECEPTORS AND GLUCAGON-LIKE PEPTIDE-1 |
| WO2017062271A2 (en) | 2015-10-06 | 2017-04-13 | Merck Sharp & Dohme Corp. | Antibody drug conjugate for anti-inflammatory applications |
| EP3383891A1 (en) | 2015-12-04 | 2018-10-10 | Novartis AG | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
| PT3387019T (pt) * | 2015-12-09 | 2022-01-14 | Scripps Research Inst | Proteínas de fusão de imunoglobulina de relaxina e métodos de uso |
| CN105505884B (zh) * | 2016-01-26 | 2017-10-03 | 郑州师范学院 | 进行抗体表达和组装的重组系统及应用 |
| EP3407916B1 (en) | 2016-01-29 | 2023-12-20 | Merck Sharp & Dohme LLC | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| KR102533456B1 (ko) * | 2016-05-18 | 2023-05-17 | 모더나티엑스, 인크. | 릴랙신을 인코딩하는 폴리뉴클레오타이드 |
| WO2017211278A1 (en) | 2016-06-06 | 2017-12-14 | Asclepiumm Taiwan Co., Ltd | Antibody fusion proteins for drug delivery |
| WO2018013483A1 (en) * | 2016-07-11 | 2018-01-18 | The California Institute For Biomedical Research | Kv1.3 channel blocking peptides and uses thereof |
| NZ753324A (en) * | 2016-12-09 | 2022-02-25 | Seagen Inc | Bivalent antibodies masked by coiled coils |
| US20200188528A1 (en) * | 2016-12-19 | 2020-06-18 | Fred Hutchinson Cancer Research Center | Peptide-antibody compositions and methods of use thereof |
| US11286301B2 (en) | 2017-02-28 | 2022-03-29 | The Board Of Trustees Of The Leland Stanford Junior University | Antifibrotic activity of CD47 blockade |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| IL322309A (en) | 2017-05-24 | 2025-09-01 | Novartis Ag | IL2 antibody grafted proteins and methods of use in cancer treatment |
| ES2910969T3 (es) | 2017-08-03 | 2022-05-17 | Amgen Inc | Muteínas de interleucina-21 y métodos de tratamiento |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP2022512688A (ja) * | 2018-10-24 | 2022-02-07 | シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用 |
| CN111234000B (zh) * | 2018-11-28 | 2023-05-26 | 鲁南制药集团股份有限公司 | 艾塞纳肽类似物 |
| IL293450A (en) | 2019-12-03 | 2022-07-01 | Evotec Int Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| JP2023514972A (ja) * | 2020-02-12 | 2023-04-12 | ザ スクリプス リサーチ インスティテュート | 長時間作用型ｇｍ－ｃｓｆおよび使用方法 |
| US20230405078A1 (en) * | 2020-03-26 | 2023-12-21 | The Regents Of The University Of California | Detection and treatment of intestinal fibrosis |
| US11325997B1 (en) | 2020-12-08 | 2022-05-10 | Chevron Phillips Chemical Company Lp | Particle size control of supported chromium catalysts in loop slurry polymerization reactors |
| CN118251420A (zh) * | 2021-04-28 | 2024-06-25 | 米诺陶治疗公司 | 人源化嵌合牛抗体和使用方法 |
| CN117794946A (zh) | 2021-06-09 | 2024-03-29 | 斯克利普斯研究所 | 长效双重gip/glp-1肽缀合物及使用方法 |
| WO2025235931A2 (en) * | 2024-05-09 | 2025-11-13 | Aptamino, Llc | Antibody structures comprising helical complementarity determining regions |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| GB9501079D0 (en) | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| JPH10245397A (ja) | 1997-03-03 | 1998-09-14 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | α−ヘリカルコイルドコイル構造を有するペプチド |
| GB9714680D0 (en) * | 1997-07-11 | 1997-09-17 | Medical Res Council | Recombinant production of proteins |
| US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
| US20030143234A1 (en) | 1999-08-20 | 2003-07-31 | Wenyuan Shi | Anti-microbial targeting chimeric pharmaceutical |
| CA2382766A1 (en) * | 2001-04-20 | 2002-10-20 | Azad Kaushik | Novel bovine vdj cassette, bf1h1, suitable for antigenization |
| US7736652B2 (en) | 2002-03-21 | 2010-06-15 | The Regents Of The University Of California | Antibody fusion proteins: effective adjuvants of protein vaccination |
| CN100389128C (zh) * | 2004-06-18 | 2008-05-21 | 上海美恩生物技术有限公司 | 肿瘤坏死治疗单抗-白细胞介素2的融合蛋白及其制法和用途 |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| PT2650020T (pt) | 2005-05-06 | 2016-12-12 | Providence Health & Services - Oregon | Proteína de fusão de imunoglobulina ox-40 trimérica e métodos do campo de utilização |
| BRPI0612529A2 (pt) | 2005-06-20 | 2010-11-23 | Psma Dev Company Llc | conjugados de anticorpo-medicamento de psma |
| US20070264687A1 (en) * | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| WO2007076923A1 (en) * | 2006-01-04 | 2007-07-12 | Merck Patent Gmbh | Combination therapy using anti-egfr and anti-her2 antibodies |
| CN101868246A (zh) * | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| WO2009132287A2 (en) * | 2008-04-24 | 2009-10-29 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| WO2011034605A2 (en) * | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| JP2011231085A (ja) * | 2010-04-30 | 2011-11-17 | Osaka Prefecture Univ | 環状ペプチド |
| EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| US8481038B2 (en) * | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| CN104039809A (zh) * | 2011-10-10 | 2014-09-10 | 希望之城公司 | 中间位和中间位结合抗体及其用途 |
| US10774132B2 (en) | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
| WO2013106489A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
| US8956000B2 (en) | 2012-07-20 | 2015-02-17 | Stephane Martinez | System and method for illumination of a rain gutter |
| US10259863B2 (en) | 2013-01-11 | 2019-04-16 | The California Institute For Biomedical Research | Bovine fusion antibodies |
| EP3019531A4 (en) | 2013-07-11 | 2017-03-15 | The California Institute for Biomedical Research | Immunoglobulin fusion proteins and compositions thereof |
| EP3022224A2 (en) | 2013-07-18 | 2016-05-25 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
| CA2935924A1 (en) | 2014-01-08 | 2015-07-16 | Tango Tech, Inc | High power portable device and docking system |
| EP2980512B1 (en) | 2014-07-31 | 2017-03-29 | Plastic Frost B.V. | Spacer |
-
2014
- 2014-07-11 EP EP14822130.2A patent/EP3019531A4/en not_active Withdrawn
- 2014-07-11 ES ES14823623T patent/ES2780948T3/es active Active
- 2014-07-11 PT PT148236235T patent/PT3019533T/pt unknown
- 2014-07-11 JP JP2016525822A patent/JP6704101B2/ja active Active
- 2014-07-11 EP EP19220077.2A patent/EP3693397B1/en active Active
- 2014-07-11 CA CA2917814A patent/CA2917814C/en active Active
- 2014-07-11 AU AU2014286998A patent/AU2014286998B2/en active Active
- 2014-07-11 US US14/903,489 patent/US20160237156A1/en not_active Abandoned
- 2014-07-11 WO PCT/US2014/046419 patent/WO2015006736A2/en not_active Ceased
- 2014-07-11 EP EP14823623.5A patent/EP3019533B1/en active Active
- 2014-07-11 KR KR1020167003585A patent/KR102361237B1/ko active Active
- 2014-07-11 WO PCT/US2014/046429 patent/WO2015006744A1/en not_active Ceased
- 2014-07-11 US US14/903,492 patent/US10683353B2/en active Active
- 2014-07-11 DK DK14823623.5T patent/DK3019533T3/da active
- 2014-07-11 CN CN201480050383.1A patent/CN105593242B/zh active Active
- 2014-07-11 CN CN202011108288.6A patent/CN112225817B/zh active Active
-
2019
- 2019-09-30 JP JP2019181052A patent/JP6952221B2/ja active Active
-
2020
- 2020-03-30 US US16/835,171 patent/US11673959B2/en active Active
-
2023
- 2023-04-21 US US18/305,292 patent/US20230365695A1/en active Pending